文献速递哮喘

重度哮喘患者对生物治疗应答与无应答感知的叙述性综述

Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.
PubMed 文献 · Eur Respir J · 2023-01-19

该叙述性综述检索四个文献数据库至2021年9月并纳入灰色文献,旨在捕捉重度哮喘患者对生物治疗应答与无应答的感知。因缺乏定性研究,仅纳入三篇论文和一份患者访谈;成人患者以疾病与治疗负担减轻界定积极应答,部分患者随时间获益减少或描述有限应答/无应答,且部分患者重视起效速度。

要点

  • 成人患者以疾病和治疗负担减轻的多维度表现界定生物治疗积极应答。
  • 部分患者随时间出现生物治疗获益减少,或描述有限应答/无应答。
  • 有限应答/无应答常置于持续住院和口服糖皮质激素治疗背景下描述。

核心结论

  • 无应答与应答的定义需以患者为中心,但目前完全缺乏聚焦该主题的定性研究。
  • 结合已发表文献与灰色文献,描述了成人重度哮喘患者对生物治疗应答的感知。

研究设计与样本

  • 叙述性综述,检索四个文献数据库自建库至2021年9月,并在患者代表参与下检索灰色文献。
  • 采用主题分析法进行综合;未发现专门探讨重度哮喘患者对生物治疗应答看法的定性研究。
  • 纳入三篇论文和一份已发表的哮喘患者访谈,并纳入来自在线讨论论坛、博客和社交媒体网站的相关灰色文献。

主要发现

  • 成人患者以疾病负担和治疗负担减轻来界定生物治疗的积极应答,两者均是多方面的。
  • 部分患者随时间推移经历生物治疗获益减少。
  • 一组患者描述对生物治疗应答有限或无应答,该情况是在持续住院和口服糖皮质激素治疗的背景下描述的。
  • 部分患者认为获益起效速度很重要。

临床怎么用

  • 临床评估生物治疗应答时需关注患者感知的疾病负担与治疗负担减轻,而非仅依据单一临床指标。
  • 对持续住院或口服糖皮质激素治疗的患者,应警惕有限应答或无应答的可能。
  • 部分患者重视获益起效速度,临床沟通与评估中可予以关注。

局限性

  • 无定性研究专门探讨重度哮喘患者对生物治疗应答的看法。
  • 仅纳入三篇论文和一份已发表的患者访谈,证据基础有限。
  • 尚未了解儿童和青少年重度哮喘患者及其照护者的观点。
  • 尚未了解真实世界环境中多样化患者的体验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are now many biological therapies to treat severe asthma. To assess which work best for which patient, we need to develop definitions of response. This narrative review aims to capture severe asthma patients' perceptions about non-response and response to biological therapy. METHODS: Four bibliographic databases were searched from inception to September 2021. Grey literature was searched with the involvement of patient representatives. A thematic approach was used for synthesis. No qualitative studies specifically explore patients' perspectives on response to biological therapy for severe asthma. Three papers and one published asthma patient interview were included. Relevant grey literature was included from online discussion forums, blogs and social media websites. RESULTS: Adult patients framed positive response to biological therapy in terms of reduced burden of disease and treatment. Both were multifaceted. Some patients experienced reduced benefit from biological therapy over time. There was a group of patients who described a limited response or non-response to biological therapy. This was framed within the context of continuing hospitalisation and oral corticosteroid treatment. The speed of onset of benefit was felt to be important by some. CONCLUSIONS: Definitions of non-response and response need to be patient-centred, yet there is a complete lack of qualitative research focused on this topic. By combining relevant published and grey literature we have provided a description of adult patients' perceptions of response to biological therapy in severe asthma. We now need to understand the views of children and adolescents with severe asthma and their carers, and diverse patient experiences in real-world settings.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Coleman C, Khaleva E, Rattu A, et al. Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma. Eur Respir J. 2023. PMID: 36104293. doi:10.1183/13993003.00837-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。